Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients With Atrial Fibrillation

Clinical Trials Monday, November 18th, 2013

ASA: 11/12/13

Atrial fibrillation (AF) is the most common type of arrhythmia in adults and becomes more common with increased age. Management of people with AF aims at preventing thromboembolic complications, and anticoagulant treatment with vitamin K antagonists (VKAs) has been the therapy of choice for many decades. A new class of anticoagulants, the factor Xa inhibitors, seems to have several pharmacological and practical advantages over VKAs, and some have recently been approved by regulatory authorities in the United States and Europe for stroke prevention in people with AF. Read More

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.